NephroCheck® (BioMérieux, Marcy-l’Étoile, France) is a commercial product combining two urinary biomarkers, TIMP-2 and IGFBP-7, to assess the risk of AKI. The gene discussed is TIMP2; the disease is acute kidney injury.